Disulfide bridge based PEGylation of proteins

Steve Brocchini, Antony Godwin, Sibu Balan, Ji-won Choi, Mire Zloh, Sunil Shaunak

Research output: Contribution to journalArticlepeer-review

149 Citations (Scopus)


PEGylation is a clinically proven strategy for increasing the therapeutic efficacy of protein-based medicines. Our approach to site-specific PEGylation exploits the thiol selective chemistry of the two cysteine sulfur atoms from an accessible disulfide. It involves two key steps: (1) disulfide reduction to release the two cystine thiols, and (2) bis-alkylation to give a three-carbon bridge to which PEG is covalently attached. During this process, irreversible denaturation of the protein does not occur. Mechanistically, the conjugation is conducted by a sequential, interactive bis-alkylation using alpha,beta-unsaturated-beta'-mono-sulfone functionalized PEG reagents. The combination of: - (a) maintaining the protein's tertiary structure after reduction of a disulfide, (b) bis-thiol selectivity of the PEG reagent, and (c) PEG associated steric shielding ensure that only one PEG molecule is conjugated at each disulfide. Our studies have shown that peptides, proteins, enzymes and antibody fragments can be site-specifically PEGylated using a native and accessible disulfide without destroying the molecules' tertiary structure or abolishing its biological activity. As the stoichiometric efficiency of our approach also enables recycling of any unreacted protein, it offers the potential to make PEGylated biopharmaceuticals as cost-effective medicines.
Original languageEnglish
Pages (from-to)3-12
Number of pages10
JournalAdvanced Drug Delivery Reviews
Issue number1
Publication statusPublished - Jan 2008


Dive into the research topics of 'Disulfide bridge based PEGylation of proteins'. Together they form a unique fingerprint.

Cite this